-4.4 C
New York
Friday, December 5, 2025
HomeMarket News
Market NewsMarketsNews

10 Undervalued Stocks That Crushed Q2 Earnings

By Ilene
0
4899

10 Undervalued Stocks That Crushed Q2 Earnings

Pfizer, Bristol-Myers Squibb, and DraftKings are among the names that are still cheap despite impressive earnings beats.

By Bella Albrecht, Morningstar 

Amid a solid earnings picture for the second quarter, many US-listed companies are beating their estimates. Combining the results of firms in the Morningstar US Market Index that have reported earnings with the analyst expectations for those yet to publish, earnings are on track to grow 12.8% from the first quarter of 2025, slightly above last quarter’s 11.3% growth and the second-highest rate in over three years.

More here >

 

This post was originally published on this site

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

149,858FansLike
396,312FollowersFollow
2,470SubscribersSubscribe

Latest Articles

Load more

Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

Contact us: support@philstockworld.com

© Copyright - PSW, LLC.

2025
0
Would love your thoughts, please comment.x
()
x